Advertisement

Comparison of Bleeding and In-Hospital Mortality in Asian-Americans Versus Caucasian-Americans With ST-Elevation Myocardial Infarction Receiving Reperfusion Therapy

Published:January 05, 2012DOI:https://doi.org/10.1016/j.amjcard.2011.11.019
      Concern has been raised that Asian-Americans may have a higher bleeding risk than Caucasian-Americans when treated with fibrinolytic and antithrombotic agents. To date there is limited evidence to support or refute this hypothesis or evaluate bleeding risk and its related outcomes in Caucasian-Americans versus Asian-Americans with ST-segment elevation myocardial infarction (STEMI) undergoing primary percutaneous coronary interventions (PPCI). We evaluated Asian-Americans and Caucasian-Americans with STEMI receiving reperfusion therapy in the National Registry of Myocardial Infarction (NRMI) 4 and 5 (n = 90,317). We studied risk-adjusted major bleeding and in-hospital mortality. Major bleeding rates after fibrinolysis were similar in Asian-Americans (n = 705) and Caucasian-Americans (n = 42,243, 11.1% vs 10.3%, adjusted odds ratio [OR] 0.97, 95% confidence interval [CI] 0.69 to 1.36, p = 0.5002). Although the observed major bleeding rate was higher in Asian-Americans (n = 1,037) compared to Caucasian-Americans (n = 46,332) treated with PPCI (10.3% vs 7.8%, p = 0.0036), these rates differed only marginally after adjusting for baseline clinical variables (OR 1.24, 95% CI 0.97 to 1.59). Overall adjusted mortality was similar in Asian-Americans and Caucasian-Americans when treated with fibrinolysis (OR 0.96, 95% CI 0.56 to 1.65) or with PPCI (OR 1.35, 95% CI 0.85 to 2.13). Major bleeding after PPCI or fibrinolysis was associated with similar increased risks for mortality in these ethic groups. In conclusion, despite suggestions to the contrary, Asian-Americans with STEMI treated with fibrinolysis or PPCI had similar bleeding and bleeding-related mortality risks compared to Caucasian-Americans. Given the genotypic and phenotypic differences between the 2 cohorts, similar studies in the rapidly growing Asian-American population are needed to confirm our findings and to understand the safety and effectiveness of newer potent antiplatelet and antithrombotic agents in patients with coronary syndromes.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to American Journal of Cardiology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Gao R.
        • Li X.
        Risk assessment and aspirin use in Asian and Western populations.
        Vasc Health Risk Manag. 2010; 6: 943-956
        • Lin L.J.
        • Cheng M.H.
        • Lee C.H.
        • Wung D.C.
        • Cheng C.L.
        • Kao Yang Y.H.
        Compliance with antithrombotic prescribing guidelines for patients with atrial fibrillation—a nationwide descriptive study in Taiwan.
        Clin Ther. 2008; 30: 1726-1736
        • Ueshima S.
        • Matsuo O.
        The differences in thrombolytic effects of administrated recombinant t-PA between Japanese and Caucasians.
        Thromb Haemost. 2002; 87: 544-546
        • Sharma V.K.
        • Tsivgoulis G.
        • Tan J.H.
        • Wong L.Y.
        • Ong B.K.
        • Chan B.P.
        • Teoh H.L.
        Feasibility and safety of intravenous thrombolysis in multiethnic Asian stroke patients in Singapore.
        J Stroke Cerebrovasc Dis. 2010; 19: 424-430
        • Wang T.Y.
        • Chen A.Y.
        • Roe M.T.
        • Alexander K.P.
        • Newby L.K.
        • Smith Jr, S.C.
        • Bangalore S.
        • Gibler W.B.
        • Ohman E.M.
        • Peterson E.D.
        Comparison of baseline characteristics, treatment patterns, and in-hospital outcomes of Asian versus non-Asian white Americans with non-ST-segment elevation acute coronary syndromes from the CRUSADE quality improvement initiative.
        Am J Cardiol. 2007; 100: 391-396
        • Babaev A.
        • Frederick P.D.
        • Pasta D.J.
        • Every N.
        • Sichrovsky T.
        • Hochman J.S.
        • NRMI Investigators
        Trends in management and outcomes of patients with acute myocardial infarction complicated by cardiogenic shock.
        JAMA. 2005; 294: 448-454
        • McNamara R.L.
        • Wang Y.
        • Herrin J.
        • Curtis J.P.
        • Bradley E.H.
        • Magid D.J.
        • Peterson E.D.
        • Blaney M.
        • Frederick P.D.
        • Krumholz H.M.
        • NRMI Investigators
        Effect of door-to-balloon time on mortality in patients with ST-segment elevation myocardial infarction.
        J Am Coll Cardiol. 2006; 47: 2180-2186
        • Pinto D.S.
        • Kirtane A.J.
        • Nallamothu B.K.
        • Murphy S.A.
        • Cohen D.J.
        • Laham R.J.
        • Cutlip D.E.
        • Bates E.R.
        • Frederick P.D.
        • Miller D.P.
        • Carrozza Jr, J.P.
        • Antman E.M.
        • Cannon C.P.
        • Gibson C.M.
        Hospital delays in reperfusion for ST-elevation myocardial infarction: implications when selecting a reperfusion strategy.
        Circulation. 2006; 114: 2019-2025
        • Rathore S.S.
        • Curtis J.P.
        • Chen J.
        • Wang Y.
        • Nallamothu B.K.
        • Epstein A.J.
        • Krumholz H.M.
        • National Cardiovascular Data Registry
        Association of door-to-balloon time and mortality in patients admitted to hospital with ST elevation myocardial infarction: national cohort study.
        BMJ. 2009; 338: b1807
        • Fazel R.
        • Krumholz H.M.
        • Bates E.R.
        • French W.J.
        • Frederick P.D.
        • Nallamothu B.K.
        • National Registry of Myocardial Infarction (NRMI) Investigators
        Choice of reperfusion strategy at hospitals with primary percutaneous coronary intervention: a National Registry of Myocardial Infarction analysis.
        Circulation. 2009; 120: 2455-2461
        • Rogers W.J.
        • Canto J.G.
        • Lambrew C.T.
        • Tiefenbrunn A.J.
        • Kinkaid B.
        • Shoultz D.A.
        • Frederick P.D.
        • Every N.
        Temporal trends in the treatment of over 1.5 million patients with myocardial infarction in the US from 1990 through 1999: the National Registry of Myocardial Infarction 1, 2 and 3.
        J Am Coll Cardiol. 2000; 36: 2056-2063
        • Mehta R.H.
        • Stebbins A.
        • Lopes R.D.
        • Rao S.V.
        • Bates E.R.
        • Pieper K.S.
        • Armstrong P.W.
        • Van de Werf F.
        • White H.D.
        • Califf R.M.
        • Alexander J.H.
        • Granger C.B.
        Race, bleeding, and outcomes in STEMI patients treated with fibrinolytic therapy.
        Am J Med. 2011; 124: 48-57
        • Ross A.M.
        • Gao R.
        • Coyne K.S.
        • Chen J.
        • Yao K.
        • Yang Y.
        • Qin X.
        • Qiao S.
        • Yao M.
        • TUCC Investigators
        A randomized trial confirming the efficacy of reduced dose recombinant tissue plasminogen activator in a Chinese myocardial infarction population and demonstrating superiority to usual dose urokinase: the TUCC trial.
        Am Heart J. 2001; 142: 244-247
        • Chen Z.M.
        • Jiang L.X.
        • Chen Y.P.
        • Xie J.X.
        • Pan H.C.
        • Peto R.
        • Collins R.
        • Liu L.S.
        • COMMIT (ClOpidogrel and Metoprolol in Myocardial Infarction Trial) Collaborative Group
        Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial.
        Lancet. 2005; 366: 1607-1621
        • Dang M.T.
        • Hambleton J.
        • Kayser S.R.
        The influence of ethnicity on warfarin dosage requirement.
        Ann Pharmacother. 2005; 39: 1008-1012
        • Cheung C.M.
        • Tsoi T.H.
        • Huang C.Y.
        The lowest effective intensity of prophylactic anticoagulation for patients with atrial fibrillation.
        Cerebrovasc Dis. 2005; 20: 114-119
        • Morimoto T.
        • Nakayama M.
        • Saito Y.
        • Ogawa H.
        Aspirin for primary prevention of atherosclerotic disease in Japan.
        J Atheroscler Thromb. 2007; 14: 159-166
        • Yamada Y.
        • Metoki N.
        • Yoshida H.
        • Satoh K.
        • Kato K.
        • Hibino T.
        • Yokoi K.
        • Watanabe S.
        • Ichihara S.
        • Aoyagi Y.
        • Yasunaga A.
        • Park H.
        • Tanaka M.
        • Nozawa Y.
        Genetic factors for ischemic and hemorrhagic stroke in Japanese individuals.
        Stroke. 2008; 39: 2211-2218
        • Rao S.V.
        • Eikelboom J.A.
        • Granger C.B.
        • Harrington R.A.
        • Califf R.M.
        • Bassand J.P.
        Bleeding and blood transfusion issues in patients with non–ST-segment elevation acute coronary syndromes.
        Eur Heart J 2007. 2007; 28: 1193-1204
        • Agostoni P.
        • Biondi-Zoccai G.G.
        • De Benedictis M.L.
        • Rigattieri S.
        • Turri M.
        • Anselmi M.
        • Vassanelli C.
        • Zardini P.
        • Louvard Y.
        • Hamon M.
        Radial versus femoral approach for percutaneous coronary diagnostic and interventional procedures; Systematic overview and meta-analysis of randomized trials.
        J Am Coll Cardiol. 2004; 44: 349-356
        • Rao S.V.
        • Jollis J.G.
        • Harrington R.A.
        • Granger C.B.
        • Newby L.K.
        • Armstrong P.W.
        • Moliterno D.J.
        • Lindblad L.
        • Pieper K.
        • Topol E.J.
        • Stamler J.S.
        • Califf R.M.
        Relationship of blood transfusion and clinical outcomes in patients with acute coronary syndromes.
        JAMA. 2004; 292: 1555-1562